PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective

Announcing a new review article publication for Acta Materia Medica journal.  Mouse double minute 2 (MDM2) is an oncogenic E3 ligase that effectively degrades the tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt MDM2-p53 binding have been discovered and developed. Given that MDM2 and p53 form an auto-regulatory loop, in which p53 undergoes targeted degradation as a substrate of MDM2, and p53 targets MDM2 for transcriptional upregulation, these MDM2 inhibitors have limited efficacy. After rapid in vivo clearance of the MDM2 inhibitors, p53 is degraded by accumulated MDM2. Fortunately, proteolysis targeting chimeras (PROTACs), a novel therapeutic strategy, overcome the limitations of MDM2 inhibitors. Several MDM2 inhibitors developed in the past two decades have been used in PROTAC technology in two applications: 1) binding and targeting endogenous MDM2 for PROTAC-based degradation and 2) binding endogenous MDM2 as a PROTAC E3 ligand for PROTAC-based degradation of other oncogenic proteins.

In this review, the authors summarize current progress in the discovery and development of MDM2-based PROTAC drugs, and discuss future perspectives and challenges in their application as effective treatments for human cancer.

Article Reference: Xin Han, Wenyi Wei and Yi Sun. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Materia Medica. Vol. 1(2):244-259. DOI: 10.15212/AMM-2022-0010

Keywords: MDM2, E3 ligase ligand, PROTAC, degradation, human cancer, drug discovery

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at

Queries about the journal can be sent to

Please visit to learn more about the journal.

Editorial Board:

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter  ; Facebook (

eISSN 2737-7946